Music lessons from home might boost brain power in cancer survivors
NCT ID NCT07052916
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study is testing whether music therapy delivered over video calls is a practical way to help blood cancer survivors who have trouble with memory, attention, and thinking. Researchers will enroll 60 adults who have had lymphoma, leukemia, or myeloma. Participants will either receive music therapy or music education sessions once a week for 12 weeks. The main goal is to see if people can stick with the program, but the study will also look at whether it improves thinking, mood, and fatigue.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- music therapy
- What this could lead to
- If this works, it could point toward a practical, home-based treatment to help blood cancer survivors with memory, attention, and thinking problems.
- What could go wrong
- This is a very early pilot study with only 60 people. It is testing if the approach is practical, not yet if it works. The results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * English-proficient, aged 18 or older * Diagnosis of lymphoma, leukemia, or myeloma * Stable oncologic disease or no evidence of disease as indicated in the medical chart or by the oncology team * Score of \<54 on the FACT-Cog PCI subscale * Minimum life expectancy of one year as per clinician assessment * Patient should be able to understand and complete all study assessments on their own. * Eligible patient should be able to understand informed consent and provide signed informed consent in English. Exclusion Criteria: * Less than 3 months since completion of surgery, radiation, induction chemotherapy (for newly diagnosed or relapsed disease), transplantation, or immunotherapy (e.g., CAR T-Cell, bispecific antibodies) * If there is a defined treatment period, the patient must be at least 3 months from treatment completion * If the patient is on continuous therapy, patient must have completed at least 6 months of the therapy * Maintenance therapies are allowed * Received music therapy (MT) in the past year * Current music training, \>6 months of music training in the past 10 years, or plan to initiate music training during the study * No access to an internet-connected device * Active suicidal ideation, bipolar, schizophrenia, or substance abuse * BOMC score ≥10 (indicative of dementia) * Uncorrectable visual, auditory, or motor impairments * Initiation or altered dose of sedative, stimulant, or anti-cholinergic medications in the past month or plan to initiate these medications during the study, as these are known to impact cognitive function * Initiation of any other interventions for CRCD (e.g., cognitive rehabilitation) in the past month or plan to initiate these interventions during the study, as these are known to impact cognitive function
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Blood cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
7 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Memorial Sloan Kettering Basking Ridge (All protocol activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (All protocol activities)
RECRUITINGMontvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All protocol activities)
RECRUITINGNew York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center Suffolk - Commack (All protocol activities)
RECRUITINGCommack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (All protocol activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (All protocol activities)
RECRUITINGUniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester (All protocol activities)
RECRUITINGHarrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mitochondria-Targeting drug gamitrinib tested for first time in humans
- Reprogrammed immune cells target CD30-Positive lymphoma in early trial
- Can an experimental pill boost cancer immunotherapy? early trial puts HG146 to the test
- Double-Drug attack on Hard-to-Treat lymphomas
- Chemotherapy plus immunotherapy tested against rare EBV-Driven immune storm
- Can a new drug combo improve myeloma treatment for older adults?